splenic marginal zone lymphoma 7 - springer splenic marginal zone lymphoma 129 revised diagnostic...

127A. Younes, B. Coiffier (eds.), Lymphoma, Current Clinical Oncology, Vol. 43,DOI 10.1007/978-1-62703-408-1_7, © Springer Science+Business Media, LLC 2013

C. Thieblemont, MD, PhD (*)Department of Hemato-Oncologie, Hôpital Saint-Louis-APHP,1 Av Claude Vellefaux, Paris 75010, Francee-mail: [email protected]

F. Davi, PhDDepartment of Hematology Biology, Hôpital Pitié–Salpetriere, APHP,47-83 Boulevand de l’Hopital, Paris 75013, France

7

Abstract

Splenic marginal zone lymphoma (SMZL) shares a common cell of origin from the “marginal zone” (MZ), with extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) and nodal mar-ginal zone lymphoma (NMZL). However, SMZL displays different clini-cal characteristics, reflecting probable biological variations according to the organ.

Within the past decade, new data regarding pathogenic mechanisms as well as therapeutic advances have been reported. Clinically, SMZL pres-ents as an indolent disseminated disease at diagnosis with specific clinical presentation including predominant enlarged splenomegaly and autoim-mune manifestations in 15 % of the patients. Diagnosis may be difficult among other small B-cell lymphomas, and the criteria for diagnosis have been recently improved. The therapeutic approaches comprise splenec-tomy or immunochemotherapy, but without consensus about the best treat-ment, except when associated with hepatitis C virus.

We are addressing here the current knowledge on the biological findings, clinical features, and therapeutic approaches for SMZL.

Keywords

Splenic marginal zone lymphoma (SMZL) • Diagnostic criteria • Splenectomy • Immunochemotherapy • Rituximab • Chemotherapy

Splenic Marginal Zone Lymphoma

Catherine Thieblemont, Frederic Davi, and Josette Brière

J. Brière, MD, PhDDepartment of Pathology, Hôpital Saint-Louis, APHP,1 Av Claude Vellefaux, Paris 75010, France

128 C. Thieblemont et al.

Introduction

Marginal zone lymphomas (MZL) represent a group of lymphomas that originate from memory B lymphocytes normally present in a distinct microanatomic compartment, the so-called mar-ginal zone (MZ) of the secondary lymphoid fol-licles. The MZ is developed in those lymphoid organs where an abundant influx of antigens is known to occur. The MZ is especially developed in spleen and mucosa-associated lymphoid tis-sues, whereas it is rarely identifiable in lymph nodes [1]. According to the sites involved and characteristic molecular findings, the International Lymphoma Study Group distinguished three dis-tinct subtypes of MZL: (1) extranodal MZL of mucosa-associated lymphoid tissue (MALT) type (MALT lymphoma), (2) splenic MZL (SMZL), and (3) nodal MZL (NMZL) [2]. Despite these advances in classification, patients with general-ized disease at diagnosis are not easily ascribed to precise diagnostic groups. The relative rarity of these lymphomas, as well as the difficulties in distinguishing them from other low-grade lym-phoma subtypes, poses crucial issues for the con-duct of epidemiological surveys and for the accurate description of clinical features and out-comes. The present review will focus on the most recent data on the diagnostic and the treatment of SMZL.

Epidemiology: Role of Hepatitis C Virus

In adults, MZLs account for 5–17 % of all non-Hodgkin lymphoma (NHL) depending on the series. SMZL represents 20 % of MZL and accounts for less than 2 % of NHL [3]. The median age of occurrence is 65 years [4, 5]. Clear evidence indicates that MZLs in extranodal local-izations as well as in spleen for SMZL and in lymph node for NMZL can be associated with chronic antigenic stimulation. Hepatitis C virus (HCV) has been highly correlated with SMZL [6], sometimes with the presence of cryoglobulin [7], lymphoplasmacytic immunocytoma, and NMZL, in some area such as in Italy [8].

A decrease in lymphoproliferation following antiviral treatments [9] reinforces the data sug-gesting this contribution of chronic antigenic stimulation to the physiopathologic process of HCV-related MZL. Interestingly, SMZL, here denominated as tropical splenic lymphoma, char-acterized by splenomegaly and circulating naive CD5-negative villous B lymphocytes, has been described in malaria-endemic areas, this supports the role of infectious agents on the pathogenesis of SMZL [10].

Clinical Features

Presentation

The hallmark of the clinical presentation of SMZL is massive splenomegaly. However, most of the patients seek medical attention because of an abnormal blood cell count, especially anemia and/or thrombocytopenia. These abnormalities are more related to splenic sequestration than to bone marrow infiltration and are consistently asso-ciated with lymphocytosis [11]. These patients are usually asymptomatic, but splenomegaly is detectable on clinical exam. In advanced cases of SMZL, patients present with a massive sple-nomegaly associated with asthenia and left upper quadrant pain. B symptoms are uncommon.

Autoimmune Manifestations

Serum lactate dehydrogenase (LDH) level is usu-ally normal in SMZL, but the b[beta]2-micro-globulin level is increased. A considerable proportion of patients (10–40 % of cases) have a serum monoclonal paraprotein (M-component), mainly of the m[mu] subtype (IgM) [11, 12]. Autoimmune clinical phenomena are described in 10–15 % of patients including autoimmune hemolytic anemia, immune thrombocytopenia, cold agglutinin, circulating anticoagulant (lupus anticoagulant and/or anticardiolipin antibodies), acquired von Willebrand disease, and angioe-dema due to acquired C1-esterase inhibitor deficiency.

1297 Splenic Marginal Zone Lymphoma

Revised Diagnostic Criteria for SMZL

Spleen histology is the gold standard approach to establish the diagnosis of SMZL (Table 7.1) [13], but most of the cases of SMZL do not require splenectomy as treatment. Moreover, spleen his-tology is not sufficient and must be completed by an immunophenotype of peripheral blood +/− marrow. According to the criteria proposed by the Splenic Lymphoma Group, minimum diagno-sis criteria are based on either spleen histology plus immunophenotype of peripheral blood +/− marrow or typical peripheral blood and bone marrow morphology plus immunophenotype of peripheral blood +/− marrow. In addition, the recent revealing of recurring molecular abnor-mality is sometimes a precious help to the diagnosis.

Histology of the Spleen

Histology of the spleen shows a micronodular infiltration by a polymorphic population of B cells, including small cells, marginal cells, and scattered large-cell lymphomas involving the spleen, preferentially the white pulp but with a variable degree of red pulp involvement. The 2001 WHO classification [14] defines SMZL as a B-cell neoplasm composed of small lympho-cytes that surround and replace the white pulp follicles and merge with a peripheral zone of larger MZ-like cell including scattered trans-formed blasts, giving the characteristic bipha-sic pattern. The 2008 WHO classification [15] expanded this definition to cases lacking a cen-tral core of smaller lymphocytes and having a monophasic pattern. For those cases, other cri-teria as peripheral blood cytology, bone marrow histology, immunophenotype, and/or presence of recurrent molecular or cytogenetic abnormalities are required.

In cases with not enough criteria for a definitive diagnosis, the choice of “unclassified splenic lymphoma” is better. This term applies to small B-cell clonal lymphoproliferations involving the spleen, but which do not fall into any of the other types of B-cell lymphoid neoplasms recognized

in the WHO classification. The two best defined of these relatively rare provisional entities are splenic diffuse red pulp lymphoma [16] and hairy cell leukemia-variant. The relationship of those cases with SMZL needs to be clarified in the future. Other splenic small B-cell lymphomas not fulfilling the criteria for either of these provi-sional entities or for other better established B-cell lymphomas should be diagnosed as splenic B-cell lymphoma/leukemia, unclassifiable until more is known. Transformation to large B-cell lymphoma may also occur in SMZL as other indolent B-cell lymphomas [17].

Histology of the Bone Marrow

When the patient is not splenectomized, diagno-sis may be required of bone marrow histology. The involvement can be intrasinusoidal, paratra-becular, nodular, or diffuse. The intrasinusoidal pattern initially described as a hallmark of SMZL is usual but cannot be considered as specific as it can be observed in other small B-cell lymphomas [18].

Immunophenotype

The immunophenotypic analysis of the tumor cells shows CD19+, CD20+, CD5−, CD10−, CD23−, CD43+/−, FMC7 +/−, CD103−, bcl-2+, and cyclin D1 cells. However, the expression of CD5 is found in 15–20 % of cases. The coexpres-sion of IgM and IgD SIg is typical of SMZL. Matutes’ international score (CD5, FMC7, CD22 or CD79b, CD23, surface Ig expression) is gener-ally below 3 [13, 19].

Mutational Status of IGVH Genes

Initial analyses of the mutational status of the Ig heavy chain variable (IGHV) genes have reported the presence of somatic hypermutation in most of the cases in accordance with the origin of SMZL from a post-germinal MZ memory B cell [20]. However, more recent studies have found an


Table 7.1 Diagnostic and staging procedures for splenic marginal zone lymphoma

Procedures Recommendations Expected results

Full blood count Mandatory Presence or absence of anemia, thrombocytopenia, lymphocytosis: presence or absence

Blood cytology Mandatory Small lymphoid cells having a round nucleus with condensed chromatin and basophilic cytoplasm, with frequent short villi

Blood FCM Mandatory CD19+, CD20+, CD22+, CD79b+, CD5−, CD10−, CD23−, CD43−/+, CD24+, CD27++, FMC7++, CD76+/−, Sig+++Score matutes <3Moderate to strong intensity of IgM and IgD or Ig M alone; in rare cases, IgG or IgAPositive expression of CD5 in 15–20 %. Positive expression of CD23 in 30 % of case

Serology for hepatitis C Mandatory If HCV positive, RT-PCR for HCV RNA and virus genotyping

Cryoglobulins Mandatory if HCV positiveSerology for hepatitis B and HIV

Mandatory

CT scan of thorax, abdomen, and pelvis

Mandatory SMZL: massive splenomegaly

Bone marrow aspirate: cytology and FCM

Mandatory Identical to blood

Reticulocyte, Coombs test

Recommended Presence or absence of autoimmune hemolytic anemia

Bone marrow biopsy: morphology and IHC

Recommended Involvement initially intra-sinusal, sometimes subtle, and then nodular. Cell morphology is monomorphic, with small-to-medium size, round to oval nucleus with regular contour and a small rim of cytoplasm. Plasmacytoid features can be observedCD20+, CD79a+, CD10−, BCL6−, CD5−, CD43+, CD23−, BCL2+, CCND1−, Sig+++Moderate to strong intensity of IgM and IgD or IgM alone

Spleen/lymph node: morphology and IHC

In case of splenectomy or lymph node biopsy

Spleen: micronodular infiltration of the white pulp, with an inconstant marginal zone differentiation and a variable degree of red pulp involvement—cells are lymphoplasma-cytoid and plasma cellsCD20+, CD79a+, CD10−, BCL6−, CD5−, CD43+, CD23−, BCL2+, CCND1−, Sig+++

Autoimmune screen (ANA, anti-DNA, AMA, antithyroid, rheumatoid factor etc.)

Optional In function of clinical symptoms or biological first screen abnormalities: immune thrombocytopenia, cold agglutinin, circulating anticoagulant (lupic or cardiolipidic), acquired von Willebrand disease, and angioedema due to acquired deficit in C1-esterase inhibitor

PET scan Optional Weak SUV signal in 50 % of the patientsFISH and cytogenetic analysis

Optional SMZL: trisomy 3q (85 %) del or translocation of 7q32 (40 %) trisomy 18, 17q isochromosome, 13q14 deletion, and structural abnormalities of chr 1

IgVH status Optional Mutated in two-thirds of the casesUnmutated in one-third of the casesBiased usage: SMZL: V

H1.2, V

H1–2, V

H3–23, V

H4–34 genes

Modified from Matutes et al. [13]IHC immunochemistry, FCM flow cytometry, RT-PCR reverse-transcriptase PCR, FISH fluorescent in situ hybridiza-tion, Chr chromosome


absence of somatic mutations in one-third of studied cases, possibly reflecting a relative degree of molecular heterogeneity of SMZL [20, 21]. In addition, SMZL B cells express a biased reper-toire with preferential usage of certain IGHV genes such as IGHV1–2*04 (31 %), IGHV3–23 (8 %), and IGHV4–34 (13 %), and approximately 10 % of the cases express B cell (BCRs) with quasi-identical IGHV sequences including the antigen-binding site, strongly suggesting that antigen selection might contribute to the develop-ment of SMZL [15]. Antigen selection is particu-larly evident in HCV-associated SMZL, since a fraction of cases express a BCR having a rheu-matoid factor activity with heavy and light chain encoded by the IGHV1–69 and IGKV3–20 genes, respectively.

It has been reported that SMZLs with Vh1–2 rearrangement produce polyreactive antibodies that react against self-antigens [22]. Those fea-tures argue for antigenic interactions through highly conserved residues, located throughout the VH domain, raising the possibility of a superantigen involved in lymphomagenesis and/or that lymphomas likely derive from polyreac-tive B cells [22]. In contrast, SMZL exhibit a low frequency of somatic mutation involving non-Ig genes such as BCL6 and or PAX5, PIM1, and RHO-H, suggesting a particular differentiation pathway of the cell of origin without transit through the germinal center [23].

Cytogenetics and Molecular Abnormalities

Cytogenetic analyses in SMZL demonstrate that complex chromosomal aberrations are common (72 % of cases with an abnormal karyotype 53 % complex). Deletion of chromosome 7q31 and complete or partial trisomy 3 are the most fre-quent cytogenetic abnormalities [24–29]. The minimal common deleted region in del7q is large, comprising over 4 Mb. No tumor suppressor genes have been found in this region of deletion 7q31, and evidence supports that the deletion of a cluster of miRNAs (MIR29A and MIR29B) [30] located in this region could contribute to the

deregulation of some of the key oncogenes in this disorder, such as TCL1 [31]. Loss of sonic hedgehog gene (SHH) at 7q36.2 (four cases) and loss of protection of telomere 1 gene have been suggested [32]. A particular miRNA profile has been described [33].

Others cytogenetic alterations involving chro-mosomes 8, 9p34, 12q23–24, 18q, and 17p have been described [34]. More rare translocations involving CDK6 and cyclin D3 with IgH have been identified in small subsets of cases [35]. Del13q14.3 which constitutes the hallmark of chronic lymphocytic leukemia (CLL) when iso-lated can be observed in less than 10 % of cases. A translocation t(11;14)(q13;q32) combined with a rearrangement of bcl-1 and/or the expression of cyclin D1 was described as present in 15 % of cases diagnosed as SLVL, but these cases seem to harbor other morphological, phenotypic, and cytogenetic features suggesting a diagnosis of mantle cell lymphoma [36–38].

Recent genome-wide DNA profiling confirmed these cytogenetic data in a large series of 218 MZLs. Common abnormalities found in all sub-types (extranodal, splenic, and nodal) include gains of 3q and 18q which appeared to affect BCR signaling and Wnt-signaling, cell cycle, and apoptosis [34]. More specific abnormalities were described in SMZL such as del(7q31) and del(8p). In terms of prognostic impact, only the associa-tion with del(17p) and del(8p) was found to be associated with a significant negative impact on the outcome of SMZLs.

Overall, the only cytogenetic abnormality to be considered as typical in SMZL is the 7q32 deletion. Cytogenetic may help the diagnosis par-ticularly for differential diagnosis with CLL, hairy cell leukemia, mantle cell lymphoma, fol-licular lymphoma, or lymphoplasmacytic lym-phoma, but should not be taken in isolation.

Gene Expression Profiling

Although it cannot be applied to routine diagno-sis yet, gene expression analysis clearly shows that SMZLs have a specific transcriptional profile compared with other lymphomas,


especially small B-cell lymphomas, such as fol-licular lymphomas, lymphocytic lymphomas, and mantle cell lymphomas [31, 39]. This specific molecular signature includes genes involved in the signaling cascade of the AKT1 pathway [39] but also the BCR signaling pathway, tumor necro-sis factor (TNF), and NF-k[kappa]B targets [31]. The importance of the latter pathway in the patho-genesis of SMZL has been strongly underlined by the detection of mutually exclusive somatic mutations of NF-k[kappa]B genes such as TNFAIP3, IKBKB, MAP3K14, TRAF3, and BIRC3 in over one-third of the cases [40].

Biological and Clinical Prognostic Factors in SMZL

The median overall survival in SMZL ranges between 5 and 10 years, but in case of aggres-sive disease, seen in approximately one-third of patients, median survival is less than 4 years [41]. Clinical and biological prognostic factors have been identified by several investigators (Table 7.2) [5, 31, 42]. The Italian Intergroup of Lymphomas (IIL) have developed a prognostic model in 309 patients based on three factors (hemoglobin level less than 12 g/dL, LDH level greater than normal, and albumin level less than

3.5 g/dL) leading to a prognostic index [42]. This index allows one to separate patients into three groups displaying different 5-year survival rates: 88 % in the low-risk group (no risk fac-tor), 73 % in the intermediate-risk group (one risk factor), and 50 % in the high-risk group (more than one factor). However, this index has not yet been demonstrated to have any therapeu-tic implications. In this analysis, IPI was found to predict survival, although the multivariate analysis selected the three indicated parameters. Other biological prognostic factors have been described, such as expression of CD38, unmu-tated IGHV gene status, and expression of NF-k[kappa]B-activated genes based on gene expression analysis [31].

Histological transformation to large-cell lymphoma remains uncommon, occurring in 10–20 % of patients. Diffuse large B-cell lym-phoma, when involving the spleen, usually is characterized by one or several large nodules, very rarely involving the bone marrow. Transformation occurs within a median interval ranging from 12 to 85 months [43]. This pres-ents clinically with the appearance of general symptoms, increase in LDH level, and dissemi-nated lymphoma involvement. After histologi-cal progression, the median survival time was shortened to 26 months [5].

Table 7.2 Clinical and biological adverse prognostic factors in splenic marginal zone lymphoma

Authors n PFS OS

SMZLThieblemont et al. [5] 81 Presence

of M-componentBeta2 microglobulin ³ 3 mg/L

Presence of an immunological event

Leukocytes ³ 20 × 109/L

Lymphocytosis ³ 9 × 109/LPresence of M-componentPresence of an immunological event

Ruiz-Ballesteros et al. [31] 44 – Expression of CD38Unmutated Ig-VH gene status

Expression of NF-k[kappa]B-activated genes by GEPArcaini et al. [42] 309 – Hemoglobin <12 g/dL

Elevated LDHAlbumin >3.5 g/dL


New Therapeutic Strategies in SMZL

Treatment is required only in symptomatic patients with painful splenomegaly, with or without associated cytopenia due to hyper-splenism. Asymptomatic patients, which repre-sent a large percentage of the patients, can be appropriately managed with watchful waiting for several years. Withholding treatment does not influence the course of disease, and these patients often have stable disease for at least 10 years [7]. The only exception to this manage-ment approach is in the setting of SMZL associ-ated with active HCV infection. Antiviral therapy with pegylated interferon-a[alpha] and ribavirin will lead to clearance of HCV RNA in 75 % of the patients and in concomitant clinical remis-sion of the lymphoma [44].

When patients become symptomatic because of anemia (<10 g/dL), abdominal pain, and thrombocytopenia (<80 × 109/L) [42], several treatment options may be proposed to the patient. Splenectomy will rapidly improve performance

status and correct anemia, thrombocytopenia, and neutropenia within 6 months after splenec-tomy [11]. This improvement is maintained for years with a median period of freedom from treatment of 8 years, even if bone marrow and blood lymphocytosis persist, suggesting a partial response. Following splenectomy, adjuvant che-motherapy provides an increased remission rate without modifying relapse-free and overall sur-vival [5]. For patients who are unfit for splenec-tomy or unwilling to undergo surgery, systemic therapy may be effective (Table 7.3) [6, 11, 45–50]. Rituximab alone is reported to afford excel-lent response rate with a shorter PFS than that observed when rituximab is combined with cladribine or fludarabine for polychemotherapy [6, 11, 47–52]. Recently, bendamustine has emerged as a highly effective drug for NHL, including marginal zone lymphomas [53]. A European trial for the evaluation of combined rituximab and bendamustine for these patients is scheduled to begin in the near future (EudraCT number 2011–000880–28). For clinical trials

Table 7.3 Response to treatment in splenic marginal zone lymphoma

Authors n ScheduleStatus of disease

Response rate CR/CRu PR

PFS (At n years)

OS (At n years)

Splenectomy aloneChacon et al. 2002 [45] 29 – First line 100 % 0 % 100 %Thieblemont et al. [11] 25 – First line 100 % 0 % 100 % 71 % (2) 81 % (5)Chemotherapy aloneLefrere et al. [46] 10 Fludarabine Relapsed 100 % 70 % 30 % 42 % (4.7). 50 % (5)Cervetti et al. [50] 50 2-Cda,

5 mg/m2, once a week × 6

First line or relapsed

63 % 62 % – 83 % (2) NA

Rituximab aloneTsimberidou et al. [47] 26 R once a

week × 4 or 8First line 88 % 43 % 46 % 86 % (3) 95 % (3)

Kalpadakis et al. [48] 16 R once a week × 6

First line 100 % 79 % 11 % 92 % (2.1) 100 % (3)

Bennett et al. [49] 14 R once a week × 4

First line 78 % 57 % 21 % 60 % (6) 80 % (6)

Rituximab and chemotherapyTsimberidou et al. [47] 6 R-FMD or RFC First line 83 % 34 % 50 % 100 % (3) 100 % (3)Arcaini et al. [6] 3 R-CVP First line 100 % – – 100 % (1.3) 100 % (1.3)

Only survivals of the whole series of patients (n = 60) treated by splenectomy with or without adjuvant chemotherapy is provided by the authors


to be evaluated, it is necessary to develop consistent staging and response criteria for the disease. The recent workshop of the European MZL group has redefined these parameters (Table 7.4) [13, 17].

Conclusion

SMZL is considered as a distinct entity among NHLs, with definite clinical and morphological characteristics. Although this entity is charac-terized by very different clinical presentations, strong similarities in the epidemiology and the biology of the tumors cells support a common origin in the memory B cells of the marginal zone. In the past 5 years, a large collaborative effort by biologists, pathologists, and clinicians has resulted in agreement on more stringent criteria for the diagnosis of the disease and for the evaluation of clinical response. These efforts should support the design of further prospective clinical trials to define the optimal therapeutic approach to these diseases.

References

1. Weill JC, Weller S, Reynaud CA. Human marginal zone B cells. Annu Rev Immunol. 2009;27:267–85. ** Outstanding review of physiology of human mar-ginal zone.

2. Swerdow SH, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissue. Lyon: IARC; 2008.

3. Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood. 2000;95:1950–6.

4. Oscier D, Owen R, Johnson S. Splenic marginal zone lymphoma. Blood Rev. 2005;19:39–51.

Table 7.4 Response criteria in splenic marginal zone lymphoma

Complete response Resolution of organomegaly (spleen longitudinal diameter <13 cm)Hemoglobin >12 g/dL and platelets >100 × 109/L and neutrophils >1.5 × 109/LNo evidence of circulating clonal B cells by FC (light chain-restricted B cells)No evidence of BM infiltration detected by IHCNegative DAT and normal PET scan (if positive at diagnosis)

Partial response Regression of ³50 % in all the measurable disease manifestationsNo new sites of diseaseImprovement of cytopeniasDecrease of infiltration and improvement of hemopoietic reserve at BM biopsy

No response Less than 10 % improvement on the disease manifestationsProgression >50 % of measurable signs of the disease from nadirRelapse Reappearance of any measurable sign of the disease

Modified from Matutes et al. [13]

Key Points

Diagnosis of splenic marginal zone lym-• phomas should be the subject of review by expert hematopathologists.Diagnosis of splenic marginal zone lym-• phoma can be made without spleen his-tology following expert review of a combination of blood and bone marrow

morphology, bone marrow trephine his-tology, and flow cytometry.Therapeutic options for patients with • SMZL are splenectomy, chemotherapy, and rituximab, alone or associated with chemotherapy. Rituximab therapy pro-duces a quick but usually short response, with a high overall response rate and a significant rate of complete response with negligible toxicity. This treatment is a reasonable first-line therapy and may be an alternative to splenectomy. Immunochemotherapy is indicated for fit patients with disseminated disease, constitutional symptoms, and/or signs of high-grade transformation.


5. Thieblemont C, Felman P, Berger F, et al. Treatment of splenic marginal zone B-cell lymphoma: an analy-sis of 81 patients. Clin Lymphoma. 2002;3:41–7.

6. Arcaini L, Paulli M, Boveri E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phe-notypic profiles. Cancer. 2004;100:107–15.

7. Saadoun D, Boyer O, Trebeden-Negre H, et al. Predominance of type 1 (Th1) cytokine production in the liver of patients with HCV-associated mixed cryo-globulinemia vasculitis. J Hepatol. 2004;41:1031–7.

8. Arcaini L, Burcheri S, Rossi A, et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol. 2007;18:346–50.

9. Hermine O, Lefrere F, Bronowicki J, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;11:89–94.

10. Bates I, Bedu-Addo G, Jarrett RF, et al. B-lymphotropic viruses in a novel tropical splenic lymphoma. Br J Haematol. 2001;112:161–6.

11. Thieblemont C, Felman P, Callet-Bauchu E, et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol. 2003;4: 95–103.

12. Parry-Jones N, Matutes E, Gruszka-Westwood AM, Swansbury GJ, Wotherspoon AC, Catovsky D. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol. 2003;120:759–64.

13. Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A, et al. Splenic marginal zone lym-phoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008;22:487–95. **First proposal of international criteria for diagnosis of SMZL.

14. Jaffe ES, Harris NL, Stein H, Vardiman J. World Health Organization Classification of Tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.

15. Swerdlow SH. Small B-cell lymphomas of the lymph nodes and spleen: practical insights to diagnosis and pathogenesis. Mod Pathol. 1999;12:125–40.

16. Traverse-Glehen A, Baseggio L, Bauchu EC, et al. Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? Blood. 2008;111:2253–60.

17. Dungarwalla M, Appiah-Cubi S, Kulkarni S, et al. High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis. Br J Haematol. 2008;143:71–4.

18. Boveri E, Arcaini L, Merli M, et al. Bone marrow his-tology in marginal zone B-cell lymphomas: correla-tion with clinical parameters and flow cytometry in 120 patients. Ann Oncol. 2009;20:129–36.

19. Matutes E, Morilla R, Owusu-Ankomah K, Houlihan A, Catovsky D. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance

to the differential diagnosis with other B-cell disor-ders. Blood. 1994;83:1558–62.

20. Algara P, Mateo MS, Sanchez-Beato M, et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood. 2002;99:1299–304.

21. Traverse-Glehen A, Davi F, Ben Simon E, et al. Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection. Haematologica. 2005;90:470–8.

22. Warsame AA, Aasheim HC, Nustad K, Trøen G, Tierens A, Wang V, et al. Splenic marginal zone lym-phoma with VH1–02 gene rearrangement expresses poly- and self-reactive antibodies with similar reactiv-ity. Blood. 2011;118:3331–9.

23. Traverse-Glehen A, Verney A, Baseggio L, et al. Analysis of BCL-6, CD95, PIM1, RHO/TTF and PAX5 mutations in splenic and nodal marginal zone B-cell lymphomas suggests a particular B-cell origin. Leukemia. 2007;21:1821–4.

24. Callet-Bauchu E, Baseggio L, Felman P, et al. Cytogenetic analysis delineates a spectrum of chro-mosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases. Leukemia. 2005;19:1818–23.

25. Dierlamm J, Michaux L, Wlodarska I, et al. Trisomy 3 in marginal zone B-cell lymphoma: a study based on cytogenetic analysis and fluorescence in situ hybrid-ization. Br J Haematol. 1996;93:242–9.

26. Dierlamm J, Pittaluga S, Wlodarska I, et al. Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. Blood. 1996;87:229–307.

27. Dierlamm J, Rosenberg C, Stul M, et al. Characteristic pattern of chromosomal gains and losses in marginal zone B cell lymphoma detected by comparative genomic hybridization. Leukemia. 1997;11:747–58.

28. Salido M, Baro C, Oscier D, et al. Cytogenetic aberra-tions and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multi-center study of the Splenic B-Cell Lymphoma Group. Blood. 2010;116:1479–88. **Largest series of cyto-genetics analysis in SMZL.

29. Sole F, Woessner S, Florensa L, et al. Frequent involvement of chromosomes 1, 3, 7 and 8 in splenic marginal zone B-cell lymphoma. Br J Haematol. 1997;98:446–9.

30. Ruiz-Ballesteros E, Mollejo M, Mateo M, Algara P, Martínez P, Piris M. MicroRNA losses in the fre-quently deleted region of 7q in SMZL. Leukemia. 2007;21:2547–9.

31. Ruiz-Ballesteros E, Mollejo M, Rodriguez A, et al. Splenic marginal zone lymphoma: proposal of new diag-nostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood. 2005;106:1831–8.

32. Vega F, Cho-Vega JH, Lennon PA, Luthra MG, Bailey J, Breeden M, et al. Splenic marginal zone lymphomas


are characterized by loss of interstitial regions of chromosome 7q, 7q31.32 and 7q36.2 that include the protection of telomere 1 (POT1) and sonic hedgehog (SHH) genes. Br J Haematol. 2008;142:216–26.

33. Bouteloup M, Verney A, Rachinel N, Callet-Bauchu E, Ffrench M, Coiffier B, et al. MicroRNA expression profile in splenic marginal zone lymphoma. Br J Haematol. 2012;156:279–81.

34. Rinaldi A, Mian M, Chigrinova E, et al. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood. 2011;117:1595–604. **An insight of genomic abnormalities in SMZL.

35. Corcoran M, Mould S, Orchard J, et al. Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations. Oncogene. 1999;18:6271–7.

36. Cuneo A, Bardi A, Wlodarska I, et al. A novel recurrent translocation t(11;14)(p11;q32) in splenic marginal zone B cell lymphoma. Leukemia. 2001;15:1262–7.

37. Jadayel D, Matutes E, Dyer M, et al. Splenic lym-phoma with villous lymphocytes: analysis of bcl-1 rearrangements and expression of the cyclin D1 gene. Blood. 1994;83:3664–71.

38. Oscier DG, Matutes E, Gardiner A, et al. Cytogenetic studies in splenic lymphoma with villous lympho-cytes. Br J Haematol. 1993;85:487–91.

39. Thieblemont C, Nasser V, Felman P, et al. Small lymphocytic lymphoma, marginal zone B-cell lym-phoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagno-sis. Blood. 2004;103:2727–37. **Gene expression profiling in SMZL with the identification of specific signatures compared to small B cell lymphomas (MCL and SLL).

40. Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C, et al. Alteration of BIRC3 and multiple other NF-kB pathway genes in splenic marginal zone lymphoma. Blood. 2011;118:4930–4. **An insight in the physiopathology of SMZL.

41. Bertoni F, Zucca E. State-of-the-art therapeutics: mar-ginal-zone lymphoma. J Clin Oncol. 2005;23:6415–20.

42. Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood. 2006;107:4643–9.

43. Camacho FI, Mollejo M, Mateo MS, et al. Progression to large B-cell lymphoma in splenic marginal zone

lymphoma—A description of a series of 12 cases. Am J Surg Pathol. 2001;25:1268–76.

44. Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin’s lymphoma: a mul-ticenter Italian experience. J Clin Oncol. 2005;23: 468–73.

45. Chacon J, Mollejo M, Munoz E, et al. Splenic mar-ginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood. 2002;100:1648–54.

46. Lefrère F, Lévy V, François S, Delarue R, Ifrah N, Tilly H, et al. Fludarabine therapy in patients with splenic lymphoma with villous lymphocytes: an update. Leukemia. 2004;18(11):1924–5.

47. Tsimberidou AM, Catovsky D, Schlette E, O’Brien S, Wierda WG, Kantarjian H, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or with-out chemotherapy or chemotherapy alone. Cancer. 2006;107(1):125–35.

48. Kalpadakis C, Pangalis GA, Dimopoulou MN, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol. 2007;25: 127–31.

49. Bennett M, Sharma K, Yegena S, Gavish I, Dave HP, Schechter GP. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica. 2005;90: 856–8.

50. Cervetti G, Galimberti S, Cecconi N, Caracciolo F, Petrini M. Role of low-dose 2-CdA in refractory or resistant lymphoplasmocytic lymphoma. J Chemother. 2004;16:388–91.

51. Lefrere F, Hermine O, Belanger C, et al. Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia. 2000;14:573–5.

52. Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lym-phoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemo-therapy alone. Cancer. 2006;107:125–35.

53. Cheson BD, Friedberg JW, Kahl BS, Van der Jagt RH, Tremmel L. Bendamustine produces durable res ponses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10:452–7.

splenic marginal zone lymphoma 7 - springer splenic marginal zone lymphoma 129 revised diagnostic...

Documents